

TABLE OF CONTENTS

| | |
|--|-------------|
| ACKNOWLEDGEMENT | viii |
| LIST OF PUBLICATIONS | xii |
| ABSTRACT..... | xiii |
| TABLE OF CONTENTS | xiv |
| LIST OF FIGURES..... | xix |
| LIST OF TABLES..... | xxii |
| CHAPTER 1..... | 1 |
| Photodynamic Therapy | 1 |
| 1.1. Historical Aspects | 1 |
| 1.1.1. Phototherapy | 2 |
| 1.1.2. Photochemotherapy and Photodynamic Therapy..... | 2 |
| 1.1.3. Mechanisms in Photodynamic Therapy | 6 |
| 1.2. Photosensitization of Tissue..... | 12 |
| 1.3. Commonly used Photosensitizers..... | 12 |
| 1.4. Light Sources..... | 16 |
| 1.4.1. Laser..... | 17 |
| 1.4.2. Lamps and LEDs | 18 |
| 1.4.3. Pulsed Versus Continuous Light | 18 |
| 1.5. Dosimetry | 19 |
| 1.5.1. Penetration depth..... | 19 |
| 1.5.2. Split Dose Therapy..... | 19 |
| 1.5.3. Fluence Rate..... | 20 |

| | |
|--|-----------|
| 1.5.4. Total Light Dose..... | 20 |
| 1.5.5. Application Modes | 21 |
| 1.6. Role of Nanoparticles in PDT | 21 |
| 1.7. Goals..... | 24 |
| CHAPTER 2..... | 28 |
| <i>In Vitro</i> Photodynamic Therapy of Cervical and Laryngeal Cancer | |
| Cell Lines | 28 |
| 2.1. Material and Methods..... | 30 |
| 2.1.1. Cells and Culture Conditions..... | 30 |
| 2.1.2. Optimum uptake time of 5-ALA and Phototoxicity for cells..... | 31 |
| 2.1.3. Cytotoxicity of 5-ALA alone..... | 34 |
| 2.1.4. Photodynamic Therapy of Hep2c and HeLa cells..... | 35 |
| 2.1.5. Cellular Viability Assay | 36 |
| 2.2. Results & Discussions..... | 37 |
| 2.2.1. 5-ALA Cellular Uptake time for HeLa and Hep2c Cells..... | 37 |
| 2.2.2. Determination of 5-ALA Uptake and cytotoxicity | 39 |
| 2.2.3. Phototoxicity of HeLa Cells..... | 42 |
| 2.2.4. Photodynamic Therapy of HeLa Cells | 44 |
| 2.3. Conclusions | 46 |
| CHAPTER 3..... | 47 |
| <i>In Vivo</i> Photodynamic Therapy of Fractionated Drug | |
| Administration | 47 |
| 3.1. Materials & Methods..... | 48 |
| 3.1.1. Animals..... | 48 |

| | |
|---|-----------|
| 3.1.2. Photosensitizer..... | 48 |
| 3.1.3. Fluorescence spectroscopy system..... | 48 |
| 3.1.4. Photodynamic Therapy Apparatus..... | 49 |
| 3.1.5. Experimental Procedure | 49 |
| 3.1.6. Macroscopic and Microscopic Analysis..... | 50 |
| 3.1.7. Data Analysis Technique..... | 52 |
| 3.2. Results | 53 |
| 3.2.1. Macroscopic and Microscopic analysis..... | 53 |
| 3.3. Discussions..... | 55 |
| 3.3.1. Histopathological analysis and Light dose parameter | 55 |
| 3.4. Conclusions | 56 |
| 3.5. Tables | 56 |
| CHAPTER 5..... | 58 |
| PEGylated Nanoparticle Photodynamic Therapy..... | 58 |
| 4.1. Material and Methods..... | 59 |
| 4.1.1. Cells and Culture Conditions..... | 59 |
| 4.1.2. Photosensitizer..... | 59 |
| 4.1.3. Nanoparticle synthesis..... | 59 |
| 4.1.4. PEGylation of nanoparticles | 60 |
| 4.1.5. Scanning Electron Microscopy (SEM)..... | 60 |
| 4.1.6. Quantification of cellular uptake of 5-ALA-PEG-nanoparticle | 61 |
| 4.1.7. Cytotoxicity of 5-ALA-PEGylated-nanoparticle and PEGylated-nanoparticles | 61 |
| 4.1.8. Phototoxicity of HeLa Cells..... | 61 |
| 4.1.9. Laser Irradiation of 5-ALA-PEG-nanoparticles Incubated Cells..... | 62 |

| | |
|---|-----------|
| 4.1.10. Neutral Red uptake assay | 62 |
| 4.2. Results and Discussions | 62 |
| 4.2.1. XRD of nanoparticles | 62 |
| 4.2.2. Nano-particles size distribution | 64 |
| 4.2.3. Uptake of 5-ALA, PEGylated nanoparticles and 5-ALA-PEGylated nanoparticles by HeLa cell lines | 64 |
| 4.2.4. Cytotoxicity and Phototoxicity of different Treatment arms..... | 65 |
| 4.2.5. Rate of Internalization | 69 |
| 4.3. Conclusions | 70 |
| CHAPTER 6..... | 71 |
| Nanoconstruct-Based Combination Therapy in Pancreatic Cancer | 71 |
| 5.1. Hypothesis..... | 72 |
| 5.2. Materials and Methods..... | 72 |
| 5.2.1. Cell Culture and therapeutic agents | 72 |
| 5.2.2. Synthesis and Characterization of Nanoconstruct..... | 72 |
| 5.2.3. Photodynamic Therapy..... | 73 |
| 5.3. Dark and light activated Cytotoxicity (MTT) | 74 |
| 5.3.1. Enzymed-Linked Immunosorbent Assay (ELISA)..... | 74 |
| 5.3.2. Fluorescence Spectroscopy | 75 |
| 5.3.3. Confocal Microscopy..... | 75 |
| 5.4. Results and Discussion..... | 75 |
| 5.4.1. Encapsulation of BPD and bevacizumab improves treatment response. | 75 |
| 5.4.2. Intracellular and Extracellular avastin quantification by fluorescence spectroscopy | 77 |
| 5.4.3. Extracellular and Intracellular VEGF Proteins..... | 78 |

| | |
|---|-----------|
| 5.5. Conclusion..... | 80 |
| CHAPTER 7..... | 81 |
| Summary and Future Recommendations | 81 |
| 6.1. Summary | 81 |
| 6.2. Future Recommendations..... | 81 |
| References..... | 83 |